A fundamental way to circumvent the limited number of actionable oncogenic-driving events is to identify molecular targets that become essential in a specific tumor’s genetic landscape. Synthetic Lethality (SL) is a co-dependency of two non-essential genes, so when one of them is lost, the other becomes essential. Hence, the identification of SL via large-scale functional genomic screens offers promising new opportunities for selective therapies in cancer, with numerous new startups aiming to take this path. However, the majority of SL identified in lab screens do not have translational significance. Addressing this challenge, we developed a data-driven approach that mines The Cancer Genome Atlas (TCGA) cohort to identify SL interactions that are likely to be clinically relevant (cSLi). Based on TCGA data analysis, we estimate that our approach can significantly increase the number of patients that could benefit from precision oncology treatments. This state-of-the-art computational genomics enables us to (1) recommend the most effective drugs to combat tumors of individual patients (2) to stratify the most relevant patients for a given treatment, and finally, (3) to facilitate the development of new SL-based drugs by providing a list of reliable new targets to which no drug is currently available.
Prof. Eytan Ruppin is the Director of the Cancer Data Science Laboratory at the National Cancer Institute (NCI) in Bethesda, MD USA. Prof. Ruppin is a computational biologist whose research is focused on developing and harnessing multi-omics data to better understand the pathogenesis of cancer, its evolution and treatment. Areas of Expertise: big data analysis, machine learning, bioinformatics and computational biology, genetic interactions in cancer and immunotherapy.
Prof. Eytan Ruppin is acting as a non-paid active consultant for Pangea.
Prof. Eyal Gottlieb is the Director of the Laura and Isaac Perlmutter Chair of Cancer Research, Technion Integrated Cancer Center, Faculty of Medicine, Israel Institute of Technology, Haifa, Israel and formerly, the Director of the Cancer Metabolism Research Unit at the Cancer Research UK, Beatson Institute in Glasgow, UK. Areas of Expertise: cancer metabolism, metabolomics, drug development and precision medicine in oncology.
Prof. Gottlieb is a consultant of Pangea.
Prof. Ze’ev Ronai is the Chief Scientific Advisor at Sanford-Burnham-Prebys Medical Discovery Institute in La Jolla CA whose research is focused on rewired signal transduction pathways that can be used for cancer therapy. Area of expertise: Melanoma, protein homeostasis and targeted therapy. Dr, Ronai interest in precision medicine dates back to 1991, when he established a highly sensitive PCR approach to detect low incidence mutant oncogenes.
Prof. Ronai is a consultant of Pangea.
Formerly the Chairman of the Obstetrics Gynecology and Infertility Division in Sheba Medical Center, Tel Aviv University Israel. Eyal has extensive experience in managing medical organizations with large scale teams, has experience as a COO of a technology startup company, strong relationships with the VC industry, and experience as a director and investor in several other biotech innovative start-up companies in the computational and pharma fields.
Emmanuel brings with him more than 20 years in the Biotech start up ecosystem.
Emmanuel was the executive VP and COO of VBL Therapeutics (Nasdaq: VBLT) where he led the Business Development and Strategy Department including worldwide BD campaigns; following VBL, Emmanuel worked as a partner in a well-known European investment bank for more than 3 years.
Emmanuel holds a Pharm D from Paris University and an MBA from Northwestern, Chicago IL.
Tuvik is an experienced technical leader and entrepreneur, who has spent the last 20 years building and leading early-stage companies in the healthcare, financial and aerospace domains. He holds a degree in Mathematics and a PhD in Computational Neuroscience.